Pharsight

Drugs that contain Brexpiprazole

1. Rexulti patents expiration

REXULTI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7888362 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(2 years from now)

USRE48059 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Dec, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618109 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(2 years from now)

US8349840 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(2 years from now)

US9839637 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(2 years from now)

US10307419 OTSUKA Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof
Oct, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Dec 27, 2024
New Indication (I) May 10, 2026

Market Authorisation Date: 10 July, 2015

Treatment: Treatment of schizophrenia; Treatment of schizophrenia in adults and pediatric patients ages 13 years and older; Adjunctive treatment of major depressive disorder (mdd)

Dosage: TABLET;ORAL

How can I launch a generic of REXULTI before it's drug patent expiration?
More Information on Dosage

REXULTI family patents

Family Patents